Ixekizumab for Treating Moderate-to-Severe Plaque Psoriasis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal

The National Institute for Health and Care Excellence invited Eli Lilly and Company Ltd, the company manufacturing ixekizumab (tradename Taltz(®)), to submit evidence for the clinical and cost effectiveness of ixekizumab. Ixekizumab was compared with tumour necrosis factor-α inhibitors (etanercept,...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Pharmacoeconomics
Main Authors: Ramaekers, Bram L. T., Wolff, Robert F., Pouwels, Xavier, Oosterhoff, Marije, Van Giessen, Anoukh, Worthy, Gill, Noake, Caro, Armstrong, Nigel, Kleijnen, Jos, Joore, Manuela A.
Format: Artigo
Jezik:Inglês
Izdano: Springer International Publishing 2018
Teme:
Review Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC6021474/
https://ncbi.nlm.nih.gov/pubmed/29480455
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40273-018-0629-2
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki